V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females
HPV Infections
BIOLOGICAL: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)|BIOLOGICAL: Comparator: Placebo (unspecified)
Human Papilloma Virus (HPV) 6 Serum Antibody Titer at One Month After Completed Vaccination Series, Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers (GMT) by vaccine group.

The limit of detection of the assay was 7 mMU/ml. GMTs and confidence limits below the limit of detection are shown as "7.0"., At one month after completed vaccination series (Month 7)|Human Papilloma Virus (HPV) 11 Serum Antibody Titer at One Month After Completed Vaccination Series, Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.

The limit of detection of the assay was 8 mMU/ml. GMTs and confidence limits below the limit of detection are shown as "8.0"., At one month after completed vaccination series (Month 7)|Human Papilloma Virus (HPV) 16 Serum Antibody Titer at One Month After Completed Vaccination Series, Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.

The limit of detection of the assay was 11 mMU/ml. GMTs and confidence limits below the limit of detection are shown as "11.0"., At one month after completed vaccination series (Month 7)|Human Papilloma Virus (HPV) 18 Serum Antibody Titer at One Month After Completed Vaccination Series, Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.

The limit of detection of the assay was 10 mMU/ml. GMTs and confidence limits below the limit of detection are shown as "10.0"., At one month after completed vaccination series (Month 7)
HPV 6, 11, 16 and 18 Serum Antibody Titer at 24 Month After Completed Vaccination Series, Month 30 HPV cLIA Geometric Mean Titers by vaccine group., 24 month after completed vaccination series (Month 30)
The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females